China NMPA Drug Inspection - Chongqing Kangle Pharmaceutical Co., Ltd - Goose does not eat grass

On July 6, 2017, the State Food and Drug Administration (SFDA) issued Announcement No. 101, detailing non-compliance across 12 batches of traditional Chinese medicine decoction pieces from 10 companies, following testing by the China National Institutes for Food and Drug Control (NIFDC). Key violations included impurities found in nine batches of Centipeda minima from manufacturers such as Jilin Yuanli Pharmaceutical Co., Ltd., Anhui Baihetang Traditional Chinese Medicine Decoction Pieces Co., Ltd., Shaoyang Shennong Traditional Chinese Medicine Technology Development Co., Ltd., and Chongqing Kangdi Pharmaceutical Co., Ltd. Additionally, Anhui Bozhou Zhewan Traditional Chinese Medicine Pieces Co., Ltd. had one batch of Pangdahai containing aflatoxin, while Guangxi Zhangyitang Traditional Chinese Medicine Pieces Co., Ltd. had two batches of Huangqi that failed appearance standards. Under the framework of Articles 73, 74, and 75 of the 'Drug Administration Law of the People's Republic of China,' provincial food and drug administrations were mandated to implement immediate control measures. These actions included sealing and seizing non-compliant products, ordering sales suspension, product recalls, and requiring rectifications. Furthermore, authorities were instructed to investigate the illegal production and sale, publicly disclose handling results within three months, and report on the overall situation. Companies were also provided a mechanism to dispute product authenticity, with severe penalties threatened for confirmed manufacturers of substandard drugs.